Anagliptin Safe and Effective Option for Type 2 Diabetes Management with Potential LDL-C Benefits: Study Medha Baranwal15 July 2024 10:00 AM ISTIndia: Anagliptin, a dipeptidyl peptidase-4 inhibitor, effectively improves glucose control and is safe for managing type 2 diabetes (T2D). Its impact...
Lowering HbA1c Variability: Key to Reduced Major Clinical Events with DPP4 Inhibitors, study finds Medha Baranwal18 Jun 2024 10:00 AM ISTChina: In a significant stride forward in diabetes management, a recent study has uncovered a compelling association between initiating dipeptidyl...
DPP4 inhibitor cetagliptin effective and well-tolerated for treating patients with type 2 diabetes Medha Baranwal27 Sept 2023 11:45 AM ISTChina: A randomized double-blind, placebo-controlled phase 3 trial has shed light on the safety and efficacy of cetagliptin as monotherapy in patients...
SGLT2 inhibitor luseogliflozin bests DPP4 inhibitors among diabetes patients Medha Baranwal15 July 2023 10:30 AM ISTJapan: A recent study published in Diabetes Therapy has shown the efficacy of luseogliflozin (SGLT2 inhibitor) over DPP-4 inhibitors in the...
Gemigliptin-metformin combo leads to better glycemic control without hypoglycemia risk Medha Baranwal18 March 2023 10:30 AM ISTSouth Korea: Treatment with gemigliptin-metformin combination therapy led to the higher achievement of the glycemic target without weight gain or...
DPP-4 inhibitors tied to low hypoglycemia risk in Inpatient diabetes patients: Study MD Bureau17 Feb 2021 10:45 AM ISTInpatient blood sugar control is usually poor and insulin therapy is not always prescribed. Reluctance to initiate insulin is due to the labor...
DPP-4 inhibitors and SGLT2 inhibitors effective in diabetics after kidney transplant Medha Baranwal26 Dec 2020 12:30 PM ISTGreece:Evidence regarding the utilization of DPP-4 inhibitors and particularly SGLT2 inhibitors and GLP-1 receptor agonists is limited in renal...
DPP-4 inhibitor therapy increases risk of bullous pemphigoid in diabetes patients: JAMA Medha Baranwal9 Aug 2020 2:56 PM ISTBoston, Massachusetts: The use of DPP-4 inhibitor therapy in type 2 diabetes patients (T2D) may lead to a higher risk of bullous pemphigoid...
Vildagliptin as good as metformin in controlling blood sugar in diabetes Medha Baranwal17 Jun 2020 12:00 PM ISTDelhi: Vildagliptin or metformin showed similar protective effects on the beta-cell function, reduced insulin resistance, and blood sugar...
